|1.||Wada, Hideo: 51 articles (02/2015 - 03/2002)|
|2.||Gando, Satoshi: 48 articles (05/2015 - 08/2002)|
|3.||Asakura, Hidesaku: 29 articles (08/2015 - 06/2002)|
|4.||Nobori, Tsutomu: 25 articles (01/2013 - 03/2002)|
|5.||Levi, Marcel: 24 articles (11/2014 - 01/2002)|
|6.||Kim, Hyun Kyung: 23 articles (01/2016 - 10/2002)|
|7.||Okamoto, Kohji: 21 articles (01/2016 - 09/2003)|
|8.||Hayakawa, Mineji: 21 articles (02/2015 - 08/2002)|
|9.||Kim, Ji-Eun: 19 articles (01/2016 - 01/2007)|
|10.||Iba, Toshiaki: 18 articles (12/2015 - 06/2003)|
|1.||Melanoma (Melanoma, Malignant)
11/01/2015 - "For BRAF wild-type melanoma, the most frequently used first-line treatment was dacarbazine. "
10/01/2015 - "Vemurafenib significantly improved overall survival compared with dacarbazine in patients with metastatic or unresectable BRAF V600E-positive melanoma in the BRIM-3 trial. "
01/01/2015 - "Nivolumab significantly improved survival versus dacarbazine in previously untreated patients with metastatic melanoma in a Phase III trial. "
07/01/2013 - "Our trial suggests that Endostar plus dacarbazine is well tolerated in patients with metastatic melanoma harboring no genetic mutations popular for targeted therapy and yields a significant improvement in PFS and OS."
07/15/2013 - "Vemurafenib has clinically significant antitumor activity in metastatic melanoma, and response rates and overall and progression-free survival rates are improved when compared with dacarbazine. "
|2.||Disseminated Intravascular Coagulation
01/01/2000 - "First remission rates have increased to greater than 85% world wide, the incidence of disseminated intravascular coagulation (DIC) has declined dramatically, and 60% to 70% of patients with AML-M3 have achieved long term survival and are potentially cured."
01/01/1990 - "3) The patients with disseminated intravascular coagulation (DIC) showed statistically marked decrease of the XIIIa, the alpha 2PI, and the FN on admission and the first hospital day compared with those patients without DIC. "
01/01/1987 - "In the absence of good clinical trials, the value of ATIII replacement therapy also remains obscure; its use in congenital deficiency is largely based on anecdote, and while it may cause more rapid correction of the hemostatic defect in patients with disseminated intravascular coagulation (DIC), any improvement in morbidity or mortality resulting from ATIII replacement remains to be demonstrated."
07/03/1978 - "The reduced response of the platelets in the newborn to these aggregating agents can be considered as a protection against disseminated intravascular coagulation (DIC), particularly in high-risk situations."
06/01/2009 - "Although obstetric disease is one of the major causes of disseminated intravascular coagulation (DIC), no gold standard exists. "
01/01/2014 - "Our results suggest that TM-α is most effective for treating patients with sepsis-induced DIC when administered within the first 3 days after diagnosis."
01/01/1998 - "If DIC could be identified earlier and AT concentrate could then be given earlier in the sepsis continuum, study results for the use of AT concentrate in humans might reveal a statistically significant difference versus placebo, and the efficacy of AT concentrate for this syndrome is more likely to be proved. "
07/01/2014 - "In sepsis-related DIC, the basis for anticoagulant therapy comes from the mounting evidence for the anti-inflammatory effects which these agents possess and can prove beneficial in septic situations. "
01/01/1998 - "Studies already indicate that the therapeutic use of antithrombin (AT) concentrate may produce a more positive outcome for sepsis-associated DIC. "
05/01/2002 - "Several studies have shown that administration of ATIII in patients with sepsis related DIC is effective in shortening the duration of DIC. "
01/01/2011 - "CsA (4 mg/kg/day) plus mPSL treatment dramatically improved HPS with DIC, reduced subcutaneous tumors within 2 weeks, and finally induced complete remission (CR) after 3 months. "
12/01/2014 - "We further demonstrate that the anti-RAGE antibody treatment significantly enhanced the efficacy of the alkylating drug dacarbazine in reducing the growth rate of RAGE overexpressing tumors. "
03/01/1999 - "Biodistribution assays revealed that DIC was rapidly eliminated (60% at t=10 min), although it accumulated in tumor tissue at higher concentrations than in other tissues. "
12/01/1987 - "Seven patients had an objective response to DTIC with both improvement in quality of life and a decrease of more than 50% in tumor size on computerized tomography (CT) or liver scanning. "
12/01/1984 - "DTB, unlike DTIC, was equally effective against both the ip and the ic implanted tumor, clearly indicating that it penetrated into the CNS in therapeutic concentration. "
|5.||Hodgkin Disease (Hodgkin's Disease)
06/01/1990 - "DIC after bone marrow harvesting in a patient with Hodgkin's disease in remission."
01/01/2014 - "Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells."
12/01/2003 - "A psu dic(17;2)(p11.2;p21), leading to p53 deletion, was observed in a patient who developed a mixed cellularity Hodgkin's disease coexisting with the CLL/SLL in the same lymph node. "
12/22/1978 - "[DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)]."
07/01/2012 - "The cause of death was identified as intracerebral haemorrhage following DIC, Hodgkin's disease and recent delivery by caesarean section. "
|3.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)